CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
OS by PS in Metastatic Pancreatic Cancer Treatment- Data From an Exploratory Subgroup Analysis
<< View More Conferences
2015 San Antonio Breast Cancer Symposium
Oncology Conference Multimedia
View more videos >>
Dr. Benjamin D. Smith on Mastectomy Versus Lumpectomy for Early Breast Cancer
Dr. Ingrid Mayer on Targeted Therapies in ER+ Breast Cancer
Dr. Aditya Bardia on RAD1901 in ER-Positive Metastatic Breast Cancer
Oncology Conference Articles
Palbociclib Improves Cell Cycle Control in ER-Positive Breast Cancer
Palbociclib enhances cell cycle control when added to anastrazole in the neoadjuvant setting in women with ER-positive primary breast cancer.
Pembrolizumab Continues to Show Promise in Breast Cancer
The PD-1 inhibitor pembrolizumab had an overall response rate of 12% in PD-L1â€“positive patients with ER-positive/HER2-negative advanced breast cancer.
Neratinib DFS Benefit Sustained in 3-Year ExteNET Update
The oral pan-HER TKI neratinib continued to show similar rates of disease-free survival for patients with HER2-positive early-stage breast cancer at a 3-year analysis of the phase III ExteNET trial.
IBIS-II: Anastrozole and Tamoxifen Similar on Recurrence, but Toxicity Profiles Differ
Breast cancer recurrence was similar whether postmenopausal women with ductal carcinoma in situ received anastrozole or tamoxifen for 5 years following local excision in the IBIS-II trial.
Tamoxifen or Anastrozole? Patient Reports Can Help Decide
Patient reports of their experiences with taking either tamoxifen or anastrozole can help clinicians decide which one to recommend to individual women, new research has found.
T-DM1 Extends Survival in Heavily Pretreated HER2+ Breast Cancer
T-DM1 (ado-trastuzumab emtansine; Kadcyla) reduced the risk of death by 32% and improved median overall surviva by almost 7 months compared with physician's choice of therapy in heavily pretreated patients with HER2-positive advanced breast cancer.
Buparlisib Modestly Improves PFS in HR-Positive Advanced Breast Cancer
Treatment with the PI3K inhibitor buparlisib plus fulvestrant showed a 1.9-month extension in progression-free survival compared with fulvestrant alone in women with endocrine-resistant HR-positive/HER2-negative advanced breast cancer.
APOBEC3B Overexpression Linked to Tamoxifen Resistance
The enzyme APOBEC3B has been associated with resistance to treatment with tamoxifen in retrospective studies and xenograft models of ER-positive breast cancer.
Estrogen Receptor Mutations Linked to Lower Survival in HR+/HER2- Breast Cancer
Estrogen receptor mutations are prevalent and associated with poorer survival in patients with pretreated HR+/HER2- metastatic breast cancer.
Study Links pCR After Neoadjuvant Therapy to Improved Survival in TNBC
Achieving a pCR with standard neoadjuvant chemotherapy plus carboplatin and/or bevacizumab was associated with a survival improvement in patients with triple-negative breast cancer.
Complications, Costs Higher With Mastectomy Versus Lumpectomy for Early Breast Cancer
The risk of complications from mastectomy plus reconstruction was increased by two-fold compared with lumpectomy plus whole breast irradiation, after adjustment for other treatment differences.
Survival Better With Breast-Conserving Therapy Versus Mastectomy in Early-Stage Cancers
Women who opt for breast-conserving therapy and radiation to treat their early-stage breast cancer are about 20% more likely to be alive after 10 years compared with their counterparts who had mastectomy.
Atezolizumab/Nab-Paclitaxel Combo Shows High Response Rates in TNBC
Frontline treatment with the PD-L1 inhibitor atezolizumab combined with nab-paclitaxel showed a confirmed objective response rate of 66.7% in patients with metastatic triple-negative breast cancer.
Neoadjuvant Carboplatin Improves Disease-Free Survival in Triple-Negative Breast Cancer
Adding carboplatin to neoadjuvant chemotherapy improves disease-free survival significantly in women with triple-negative breast cancer but not HER2-positive breast cancer.
Avelumab Effective in PD-L1-Positive Metastatic Breast Cancer
Treatment with the PD-L1 inhibitor avelumab demonstrated promising overall response rates for patients with PD-L1â€“positive metastatic breast cancer, particularly for those with triple-negative disease.
Adjuvant Chemotherapy May Not Improve Outcomes in Luminal A Breast Cancer
Premenopausal women with high-risk breast cancer of the luminal A subtype derive no benefit from adjuvant chemotherapy.
Denosumab Demonstrates Survival Benefit in Postmenopausal Women
A follow-up analysis of the benefits of adding denosumab to aromatase inhibitor therapy has found that the agent not only helps to prevent fractures, it reduces the risk of recurrence and death in postmenopausal women with HR-positive breast cancer.
Adjuvant Capecitabine Improves Survival in HER2-Negative Breast Cancer
Adding capecitabine to adjuvant therapy reduced the risk of disease recurrence by 30% and prolonged survival by 40% for patients with residual breast cancer following neoadjuvant chemotherapy and surgery.
FDA Approvals in Pediatric ALL and PNH, Japanese Approves Pembrolizumab in 5 Indications, and More
FDA Issues Letter Regarding Safety Concerns With Paclitaxel-Coated Devices
Treatment Goals in Refractory mCRC
Controversy Adds Caution to CRISPR Editing in United States
FDA Grants Zanubrutinib Breakthrough Designation for Mantle Cell Lymphoma
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.